Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in Advanced Solid Tumors
NCT00264004Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2005
- Primary completion
- Jan 2007
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of cediranib in solid tumor (advanced stage) (2 arms), sponsored by AstraZeneca. Primary endpoints: Proportion of Patients Requiring Temporary or Permanent Withdrawal of AZD2171 Prior to Progression and Within 12 Weeks and Proportion of Planned Dose Received During First 12 Weeks of Therapy. Started Nov 2005; status: completed.
02
Drugs
cediranib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT00264004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264004.